Clinical Trial Update: Disitamab Vedotin (RC48-ADC) in Breast Cancer

View source ↗

Summary

A clinical trial update indicates that Disitamab Vedotin (RC48-ADC) is currently recruiting for breast cancer. The study is sponsored by RenJi Hospital.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Disitamab Vedotin (RC48-ADC) (disitamab vedotin)

Snippet

Sponsor: RenJi Hospital | Conditions: Breast Cancer | Status: RECRUITING